Prostate Cancer - Results from #180

Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer. September 25, 2024

Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. September 25, 2024

Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval. September 25, 2024

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. September 24, 2024

American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy. September 24, 2024

Virtual reality as an adjunct to traditional patient counseling in patients with newly-diagnosed localized prostate cancer. September 24, 2024

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. September 24, 2024

Whole-body MRI for staging prostate cancer: a narrative review. September 24, 2024

Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study. September 24, 2024

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France. September 23, 2024

Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial. September 23, 2024

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories. September 23, 2024

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs. September 23, 2024

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction. September 23, 2024

Beyond Medical Bills: The Indirect Costs of Prostate Cancer. September 23, 2024

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study. September 23, 2024

Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials. September 20, 2024

Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy. September 20, 2024

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial. September 20, 2024

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. September 20, 2024

Page 10 of 1435